Pfizer: Anemia, Sickle Cell trials

The registry lists 32 Anemia, Sickle Cell studies with Pfizer as lead sponsor. 1 are open to participants now and 19 have results posted.

Phase 1 10Phase 2 5Phase 3 11Phase 4 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCDRecruitingNCT05431088Phase 2/3
• Voxelotor CYP and Transporter Cocktail Interaction StudyCompletedNCT05981365Phase 1Results posted
• A GBT021601 ADME Microtracer Study in Healthy VolunteersCompletedNCT05718687Phase 1Results posted
• GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)TerminatedNCT05632354Phase 2/3Results posted
• Resolution of Sickle Cell Leg Ulcers With VoxelotorTerminatedNCT05561140Phase 3Results posted
• A Study to Learn About Sickle Cell Disease In Adult PatientsCompletedNCT05407805Results posted
• Voxelotor Neurocognitive Function StudyTerminatedNCT05228834Phase 3Results posted
• A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)CompletedNCT04983264Phase 1Results posted
• A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive CrisesCompletedNCT04935879Phase 3Results posted
• Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCDTerminatedNCT04930445Results posted
• A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive CrisesTerminatedNCT04927247Phase 3Results posted
• Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of AgeCompletedNCT04893811Phase 4Results posted
• Actigraphy Improvement With Voxelotor (ActIVe) StudyCompletedNCT04400487Phase 4Results posted
• Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCDTerminatedNCT04247594Phase 2Results posted
• Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseaseTerminatedNCT04218084Phase 3Results posted
• Open-Label Extension of VoxelotorTerminatedNCT04188509Phase 3Results posted
• Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031TerminatedNCT03573882Phase 3Results posted
• An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001CompletedNCT03041909Phase 2Results posted
• Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)CompletedNCT03036813Phase 3Results posted
• Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseTerminatedNCT02850406Phase 2Results posted
• Study of GBT021601 in Participants With Renal ImpairmentTerminatedNCT05878704Phase 1
• A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell DiseaseTerminatedNCT05348915Phase 3
• Voxelotor Brain Oxygenation and Neurocognitive StudyWithdrawnNCT05228821Phase 4
• A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy ParticipantsCompletedNCT05036512Phase 1
• Retrospective Real World Oxbryta® Data Collection and Analysis StudyCompletedNCT04930328
• Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsNo longer availableNCT04724421
• Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell DiseaseCompletedNCT04255875Phase 1
• Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsNo longer availableNCT03943615
• A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy SubjectsCompletedNCT02567695Phase 1
• Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy SubjectsCompletedNCT02567682Phase 1
• A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male SubjectsCompletedNCT02497924Phase 1
• A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell DiseaseCompletedNCT02285088Phase 1